Dedicated to treating and empowering patients
experiencing or at risk for blindness
ATSENA THERAPEUTICS is dedicated to improving the quality of life of patients with inherited retinal disease. Our gene therapy programs aim to reverse or prevent blindness in patients with X-linked retinoschisis (XLRS), GUCY2D-associated Leber congenital amaurosis (LCA1), MYO7A-associated Usher Syndrome Type 1B (USH1B), ABCA4-associated Stargardt disease, and multiple undisclosed indications.



